NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study.

ABSTRACT:

Background

Easily accessible biomarkers enabling the identification of those patients with multiple sclerosis (MS) who will accumulate irreversible disability in the long term are essential to guide early therapeutic decisions. We here examine the utility of serum neurofilament light chain (sNfL) for forecasting relapse-free disability progression and conversion to secondary progressive MS (SPMS) in the prospective Neurofilamentandlongtermoutcome inMS (NaloMS) cohort.

Methods

The predictive ability of sNfL at Baseline and sNfL follow-up (FU)/ Baseline (BL) ratio with regard to disability progression was assessed within a development cohort (NaloMS, n=196 patients with relapsing-remitting MS (RRMS) or clinically isolated syndrome) and validated with an external independent co

SUBMITTER: Uphaus T 

PROVIDER: S-EPMC8479646 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature